雅培Abbott Laboratories （ABT）2022年年度报告「NYSE」（英文版）（86页）.pdf

1、2022 ANNUAL REPORTDuring a routine physical,Jay Kings doctor discovered that Jay was suffering from atrial fibrillation.A series of ablations using Abbotts TactiCath Ablation Catheter in conjunction with the EnSite X mapping system and HD Grid Mapping Catheter helped his heart restore a steady beat.

2、Later,after suffering an episode of ventricular tachycardia,Jay had our Gallant cardioverter defibrillator implanted,which let him get back to the active life and outdoor activities he loves.JAY KINGENSITE X EP SYSTEM/ADVISOR HD GRID MAPPING CATHETER,SENSOR ENABLED/TACTICATH ABLATION CATHETER,SENSOR

3、 ENABLED/GALLANT ICDFront Cover:TABLE OF CONTENTS1 Letter to Shareholders5 Abbott 12 Rapid Diagnostics14 Laboratory Diagnostics 16 Pediatric and Adult Nutrition18 Established Pharmaceuticals20 Structural Heart22 Vascular24 Neuromodulation26 Heart Failure Management28 Electrophysiology30 Cardiac Rhyt

4、hm Management32 Diabetes Care34 Creating the Future36 Financial ReportAt Abbott,weve been relentlessly focused on improving peoples health for 135 years.Today,were tackling some of the worlds most pressing healthcare challenges to help people at all ages and stages of life.Because we believe the bes

5、t medical product is the one that helps the most people,we design breakthrough solutions in each of our businesses nutrition,branded-generic pharmaceuticals,medical devices,and diagnostics to help ensure maximum access and affordability.Our balanced leadership across diverse markets and geographies

6、gives us more ways to win and helps insulate us from the impact of global economic swings,helping us deliver consistent growth and strong shareholder returns.DEAR FELLOW SHAREHOLDER:The three years of the Covid pandemic called on all of the strengths that have made Abbott such an enduringly successf